Three seasoned observers of technology predict that 2026 will be the year artificial intelligence moves from spectacle to scar tissue—embedded quietly into the mundane operations that actually move money. The conversation cuts through the usual hype: no grand unified superintelligences, no robot armies, but rather a cascade of small, brutal efficiencies that compound fast across sectors. OpenAI adding ads to ChatGPT is treated as inevitable, not revolutionary. The more interesting claim is that both OpenAI and Anthropic will push toward IPO, having exhausted the private funding appetite. With Anthropic now raising at $10 billion, they argue the jump to $30–40 billion in capital markets becomes the rational next step.
Voice emerges as the quietly dominant modality. Eleven Labs, the European foundational model company now headquartered in Lisbon, is expected to reach a $500–600 million valuation. The logic is straightforward: as video proliferates across platforms and devices, every video needs voice. Text-to-speech becomes as essential as electricity. The thread extends to voice agents for customer support and accessibility—domains where the technology already works and users already accept it. The risk, all three acknowledge, is that audio-only interfaces sound sophisticated until they crash into real friction: a customer service bot that cannot escalate creates frustration faster than it resolves problems.
The wildcard is hardware. Apple faces a binary choice: either execute meaningfully on on-device AI through Siri and proprietary models, or accept that it will be a premium interface layer for other companies' large language models. The consensus leans toward Apple staying focused on what it does best—optimizing for specific, high-value use cases within its ecosystem (payments, recommendations, personal context) rather than competing head-to-head with OpenAI on general intelligence. Meta's recent investments in image generation and acquisitions signal a clear move to shore up its weakest modality. Nobody seriously thinks the Metaverse glasses will matter in the consumer market; they think Meta needs differentiated models to compete in feed-based, mobile-first AI experiences. Meanwhile, GLP-1 drugs shift from injectables to oral pills, lowering friction and cost—a move expected to push adoption from 13% of U.S. adults to 35% within the year. The business implication is brutal: what was a specialty pharmaceutical becomes a consumer category, closer to vitamins than medicine.
Enterprise adoption remains slow but shows signs of inflection. The barriers are not technical. A single airline or logistics company deploying agentic workflow automation effectively would force competitors to follow—the switching costs and performance gains too large to ignore. The analogy is crude but apt: translators moved wholesale to LLM-based systems within months once the quality crossed a threshold and the cost fell. The same pattern is emerging in customer support, content moderation, and supply chain optimization. What separates winners from laggards is the willingness to invest in validation research—proving that the change produces better outcomes, not just faster ones.
Education sits at the intersection of possibility and friction. Personalized tutoring powered by AI is technologically viable; what is lacking is the clinical rigor to prove it works better than incumbent methods across diverse student populations. This requires not startups but dedicated research infrastructure, similar to what Sword Health built in physiotherapy. A company that commits capital to actual validation rather than feature shipping could dominate an entire sector. The same principle applies across healthcare, legal services, and compliance—wherever expertise is scarce and expensive, but outcomes are measurable.